BRICKELL BIOTECH BBI 深 沪
已收盘 09-07 16:00:00 美东时间
2.35
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.35
- 总市值 675.39万
- 52周最高 36.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.21
- 委 比 0.00%
- 总股本 287.40万
- 历史最高 225.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.185
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nu Holdings Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Providing a diverse range of perspectives from bullish to bearish, 7 analysts h...
10-17 05:00
Boundless Bio To Present Preclinical Data On BBI-825 And BBI-355 Combo Targeting Oncogene-Amplified Cancers At AACR-NCI-EORTC 2025
Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
10-14 04:10
巴西矿业公司Atlas(JUPGF.US)完成反向拆股，IPO定价9-11美元拟募资800万美元
巴西关键矿产公司Atlas Critical Minerals向美国证券交易委员会(SEC)提交修正案，披露已完成反向股票分割操作。
10-10 14:51
特朗普支持大麻二酚用于老年人医疗，大麻类股应声上涨
美国前总统唐纳德・特朗普周末在社交媒体发文称大麻二酚可能具有健康益处，受此影响，周一盘前交易初期，大麻类企业股价出现上涨。 特朗普周日在文中表示，大麻二...
09-29 18:13
What's Going On With BlackBerry Stock Today?
BlackBerry rises after Germany's BSI certifies its UEM for Apple Indigo and Samsung Knox in government use; BB up ~3%.
09-18 23:02
盘前：纳指期货涨0.37% 甲骨文飙升30%
全球股市上涨，美元企稳，投资者正等待关键的美国通胀数据，该数据可能影响美联储的政策前景；与此同时，地缘政治不确定性推高油价，并使黄金保持在接近历史高位。 ...
09-10 20:39
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
BridgeBio Pharma将于2025年9月10日美国东部时间上午8点举办投资者网络研讨会，介绍其用于治疗遗传性低钙血症1型（ADH1）的候选药物encaleret。研讨会将由NIH的Rachel Gafni博士主持，她将详细介绍ADH1的病理、未满足的医疗需求及encaleret的治疗潜力。此外，BridgeBio的高管团队还将汇报encaleret的临床开发进展及其3期CALIBRATE研究的最新情况，预计2025年秋季发布顶线结果。投资者可访问公司网站参与实时网络直播或在活动后30天内观看回放。
09-03 11:30
Banco Bradesco BBI S.A Upgrades Nu Holdings to Outperform, Announces $17 Price Target
Banco Bradesco BBI S.A analyst Marcelo Mizrahi upgrades Nu Holdings (NYSE:NU) from Neutral to Outperform and announces $17 price target.
08-25 23:05
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
<p>BridgeBio Oncology Therapeutics, Inc. (BBOT) completed its business combination with Helix Acquisition Corp. II on August 11, 2025, closing a $261 million PIPE led by Cormorant Asset Management. Combining this with $120 million from the Helix trust account, BBOT secured approximately $382 million in gross proceeds to advance its RAS-targeted oncology pipeline. BBOT will begin trading on the Nasdaq Global Market under the ticker "BBOT" on Augus...
08-11 20:30
